- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: TAR syndrome.
Displaying page 1 of 1.
EudraCT Number: 2007-006302-13 | Sponsor Protocol Number: CT-BI Vacc-4x 2007/1 | Start Date*: 2008-06-04 | |||||||||||
Sponsor Name:Bionor Immuno AS | |||||||||||||
Full Title: A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART | |||||||||||||
Medical condition: HIV positive subjects who have been clinically stable on antiretroviral therapy for the last six months with a viral load less than 50 copies/mL for the last six months and a CD4 cell count => 400 ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005950-33 | Sponsor Protocol Number: DOMPCCHSSWE1 | Start Date*: 2006-06-07 |
Sponsor Name:Karolinska Universitetssjukhuset | ||
Full Title: Studie av Domperidon och barn med kongenitalt centralt hypoventilationssyndrom. | ||
Medical condition: Congenital central hypoventilation syndrome, CCHS or Ondine's curse. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004506-64 | Sponsor Protocol Number: 17000139BLC3002 | Start Date*: 2023-01-09 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG... | |||||||||||||
Medical condition: BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021356-26 | Sponsor Protocol Number: 111679 | Start Date*: 2011-01-03 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A Phase IIb, randomized, observer-blind, placebo controlled, multicenter primary/booster therapeutic vaccination study to determine efficacy and safety of F4co/ AS01B vaccine, administered intramus... | |||||||||||||
Medical condition: ART-naïve HIV-infected adults (ART: anti-retroviral therapy) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001348-39 | Sponsor Protocol Number: SEM-TAR-01-2014 | Start Date*: 2014-12-03 | ||||||||||||||||
Sponsor Name:Fundación pública andaluza para la gestión de la investigación en salud de Sevilla (FISEVI) | ||||||||||||||||||
Full Title: A Phase II, randomized clinical trial to assess the impact of antiretroviral therapy over viral load in seminal fluid in antiretroviral-naive HIV-positive patients | ||||||||||||||||||
Medical condition: HIV-1 infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005506-23 | Sponsor Protocol Number: NV18209 | Start Date*: 2006-04-28 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: Estudio de fase IV, multicéntrico, aleatorizado y doble ciego para comparar la seguridad y eficacia de 180 µg de Pegasys® más 1000 ó 1200 mg de Copegus® con la combinación actualmente aprobada de 1... | ||
Medical condition: Pacientes con virus de la Hepatitis C crónica (HCC) del genotipo 1 coinfectados por virus de la inmunodeficiencia humana de tipo 1 (VIH-1). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006417-32 | Sponsor Protocol Number: P04889 | Start Date*: 2008-02-06 | |||||||||||
Sponsor Name:Schering-Plough Research Institute | |||||||||||||
Full Title: Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4) | |||||||||||||
Medical condition: HIV infection (R5 tropism only) with previous therapy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003133-16 | Sponsor Protocol Number: P04875 | Start Date*: 2008-02-15 | |||||||||||
Sponsor Name:SCHERING-PLOUGH | |||||||||||||
Full Title: Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects | |||||||||||||
Medical condition: HIV INFECTION IN NAIVE PATIENTS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
